The Chairman of the Executive Board of E. Merck OHG, Jon Baumhauer, announced that the board unanimously decided to name Dr. Michael Roemer, 59, as chairman of the executive board of Merck KGaA with immediate effect. Dr. Roemer will maintain his current responsibility for production, engineering, corporate purchasing, environmental issues and logistics sectors.

Vice Chairman of the Executive Board of E. Merck OHG, Dr. Frank Stangenberg-Haverkamp, stated: “With Michael Roemer we have appointed a chairman, who in his 27 years with the company, has built a great reputation widely recognized internally and externally. We are pleased that he will lead the company into the next management generation.”

Prof. Dr. Bernhard Scheuble, 52, is resigning with mutual agreement with immediate effect. Jon Baumhauer, spokesman for the Merck family, said, “In the 24 years that Professor Scheuble worked for our company, he achieved an impressive growth in our corporate value and created new jobs. We are thankful for his great contribution and wish him well for the future.”

Also with immediate effect, Elmar Schnee, 46, will become a member of the executive board of Merck KGaA and will be responsible for the Pharmaceutical Business Sector, which until now was also led by Professor Scheuble. Schnee has broad experience in the pharmaceutical business and accomplished extraordinary achievements in various markets especially in France. He will keep his responsibility for the Pharma Ethicals division for the time being.